178 related articles for article (PubMed ID: 23652254)
1. An analytical model to determine interseed attenuation effect in low-dose-rate brachytherapy.
Safigholi H; Sardari D; Karimi Jashni S; Mahdavi SR; Meigooni AS
J Appl Clin Med Phys; 2013 May; 14(3):4226. PubMed ID: 23652254
[TBL] [Abstract][Full Text] [Related]
2. Monte Carlo investigation of I-125 interseed attenuation for standard and thinner seeds in prostate brachytherapy with phantom validation using a MOSFET.
Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D
Med Phys; 2013 Mar; 40(3):031717. PubMed ID: 23464312
[TBL] [Abstract][Full Text] [Related]
3. Investigation of interseed attenuation and tissue composition effects in (125)I seed implant prostate brachytherapy.
Mason J; Al-Qaisieh B; Bownes P; Henry A; Thwaites D
Brachytherapy; 2014; 13(6):603-10. PubMed ID: 24913435
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of dosimetric effects of metallic artifact reduction and tissue assignment on Monte Carlo dose calculations for
Assam I; Vijande J; Ballester F; Pérez-Calatayud J; Poppe B; Siebert FA
Med Phys; 2022 Sep; 49(9):6195-6208. PubMed ID: 35925023
[TBL] [Abstract][Full Text] [Related]
5. Perturbation of TG-43 parameters of the brachytherapy sources under insufficient scattering materials.
Zehtabian M; Sina S; Faghihi R; Meigooni A
J Appl Clin Med Phys; 2013 May; 14(3):4228. PubMed ID: 23652255
[TBL] [Abstract][Full Text] [Related]
6. A Monte Carlo study on the effect of seed design on the interseed attenuation in permanent prostate implants.
Afsharpour H; D'Amours M; Coté B; Carrier JF; Verhaegen F; Beaulieu L
Med Phys; 2008 Aug; 35(8):3671-81. PubMed ID: 18777927
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
Chibani O; Williamson JF; Todor D
Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
[TBL] [Abstract][Full Text] [Related]
8. A generic high-dose rate (192)Ir brachytherapy source for evaluation of model-based dose calculations beyond the TG-43 formalism.
Ballester F; Carlsson Tedgren Å; Granero D; Haworth A; Mourtada F; Fonseca GP; Zourari K; Papagiannis P; Rivard MJ; Siebert FA; Sloboda RS; Smith RL; Thomson RM; Verhaegen F; Vijande J; Ma Y; Beaulieu L
Med Phys; 2015 Jun; 42(6):3048-61. PubMed ID: 26127057
[TBL] [Abstract][Full Text] [Related]
9. Monte Carlo study of LDR seed dosimetry with an application in a clinical brachytherapy breast implant.
Furstoss C; Reniers B; Bertrand MJ; Poon E; Carrier JF; Keller BM; Pignol JP; Beaulieu L; Verhaegen F
Med Phys; 2009 May; 36(5):1848-58. PubMed ID: 19544804
[TBL] [Abstract][Full Text] [Related]
10. Accuracy assessment of the superposition principle for evaluating dose distributions of elongated and curved 103Pd and 192Ir brachytherapy sources.
Bannon EA; Yang Y; Rivard MJ
Med Phys; 2011 Jun; 38(6):2957-63. PubMed ID: 21815369
[TBL] [Abstract][Full Text] [Related]
11. Monte Carlo calculations and experimental measurements of the TG-43U1-recommended dosimetric parameters of 125I (Model IR-Seed2) brachytherapy source.
Sheikholeslami S; Nedaie HA; Sadeghi M; Pourbeigy H; Shahzadi S; Zehtabian M; Hasani M; Meigooni AS
J Appl Clin Med Phys; 2016 Jul; 17(4):430-441. PubMed ID: 27455485
[TBL] [Abstract][Full Text] [Related]
12. A generic TG-186 shielded applicator for commissioning model-based dose calculation algorithms for high-dose-rate
Ma Y; Vijande J; Ballester F; Tedgren ÅC; Granero D; Haworth A; Mourtada F; Fonseca GP; Zourari K; Papagiannis P; Rivard MJ; Siebert FA; Sloboda RS; Smith R; Chamberland MJP; Thomson RM; Verhaegen F; Beaulieu L
Med Phys; 2017 Nov; 44(11):5961-5976. PubMed ID: 28722180
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric characterization of an 192Ir brachytherapy source with the Monte Carlo code PENELOPE.
Casado FJ; García-Pareja S; Cenizo E; Mateo B; Bodineau C; Galán P
Phys Med; 2010; 26(3):132-9. PubMed ID: 20034828
[TBL] [Abstract][Full Text] [Related]
14. A dosimetric comparison of 169Yb and 192Ir for HDR brachytherapy of the breast, accounting for the effect of finite patient dimensions and tissue inhomogeneities.
Lymperopoulou G; Papagiannis P; Angelopoulos A; Karaiskos P; Georgiou E; Baltas D
Med Phys; 2006 Dec; 33(12):4583-9. PubMed ID: 17278810
[TBL] [Abstract][Full Text] [Related]
15. A CT-based analytical dose calculation method for HDR 192Ir brachytherapy.
Poon E; Verhaegen F
Med Phys; 2009 Sep; 36(9):3982-94. PubMed ID: 19810471
[TBL] [Abstract][Full Text] [Related]
16. Development of a phantom to validate high-dose-rate brachytherapy treatment planning systems with heterogeneous algorithms.
Moura ES; Micka JA; Hammer CG; Culberson WS; DeWerd LA; Rostelato ME; Zeituni CA
Med Phys; 2015 Apr; 42(4):1566-74. PubMed ID: 25832047
[TBL] [Abstract][Full Text] [Related]
17. Interseed effects on dose for 125I brachytherapy implants.
Meigooni AS; Meli JA; Nath R
Med Phys; 1992; 19(2):385-90. PubMed ID: 1584137
[TBL] [Abstract][Full Text] [Related]
18. CT-based dosimetry calculations for 125I prostate implants.
DeMarco JJ; Smathers JB; Burnison CM; Ncube QK; Solberg TD
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1347-53. PubMed ID: 10613332
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the MIM Symphony treatment planning system for low-dose-rate- prostate brachytherapy.
Dhanesar SK; Lim TY; Du W; Bruno TL; Frank SJ; Kudchadker RJ
J Appl Clin Med Phys; 2015 Sep; 16(5):62–75. PubMed ID: 26699290
[TBL] [Abstract][Full Text] [Related]
20. Dose perturbation effects in prostate seed implant brachytherapy with I-125.
Mobit P; Badragan I
Phys Med Biol; 2004 Jul; 49(14):3171-8. PubMed ID: 15357190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
